← Back to headlines
AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook
AstraZeneca has maintained its full-year outlook after reporting a profit beat in the second quarter, driven by strong sales of its cancer and rare disease drugs, with non-GAAP EPS topping expectations by $1.36.
27 Jul, 07:15 — 27 Jul, 07:15
Sources
Showing 1 of 2 sources
Coverage Timeline
First report: seeking-alpha · 27 Jul, 07:15|Full coverage: 2 · 4m|Window: 4m
Left-leaningCenterRight-leaning